These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21050361)

  • 21. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.
    Gonzalez-Roibon ND; Chaux A; Al-Hussain T; Osunkoya AO; Bezerra SM; Hicks J; Epstein JI; Netto GJ
    Hum Pathol; 2013 Apr; 44(4):612-22. PubMed ID: 23084634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
    Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
    Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications.
    Tickoo SK; Milowsky MI; Dhar N; Dudas ME; Gallagher DJ; Al-Ahmadie H; Gopalan A; Fine SW; Ishill N; Bajorin DF; Reuter VE
    BJU Int; 2011 Mar; 107(5):844-849. PubMed ID: 20707797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
    Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
    Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent.
    Ojha R; Singh SK; Bhattacharyya S; Dhanda RS; Rakha A; Mandal AK; Jha V
    J Urol; 2014 Jun; 191(6):1889-98. PubMed ID: 24440234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. hepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells.
    Wang Q; Luo C; Wu X; Du H; Song X; Fan Y
    J Urol; 2013 Nov; 190(5):1912-8. PubMed ID: 23669565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
    Kim H; Lee SJ; Lee IK; Min SC; Sung HH; Jeong BC; Lee J; Park SH
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
    Li B; Yang J; Lu Z; Liu B; Liu F
    J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer.
    Kyou Kwon J; Kim SJ; Hoon Kim J; Mee Lee K; Ho Chang I
    Urol Oncol; 2014 Jan; 32(1):51.e27-35. PubMed ID: 24239466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
    Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
    Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
    Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
    Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
    Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
    Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
    Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
    J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.